Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations

Overview

Journal JBMR Plus

Publisher Oxford University Press

Date 2023 Oct 9

PMID 37808399

Authors

Ariadne Bosman

Danielle Ma Ratsma

Bram Cj van der Eerden

M Carola Zillikens

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor (FGF)23 is one of the major regulators of phosphate homeostasis. Hypophosphatemia can lead to muscle weakness, fatigue, and osteomalacia. In the setting of hypophosphatemia, serum FGF23 can be measured to differentiate between FGF23-mediated and non-FGF23-mediated renal phosphate wasting. C-terminal FGF23 (cFGF23) assays detect both cFGF23 and intact FGF23 (iFGF23). Circulating FGF23 is regulated by 1.25-dihydroxy-vitamin D, parathyroid hormone (PTH), serum phosphate, and serum calcium but also by, for example, iron status, inflammation, erythropoietin, and hypoxia-inducible-factor-1-α. We present the case of a 48-year-old woman with unexplained mild hypophosphatemia, very high cFGF23, and normal iFGF23. The patient proved to have an iron deficiency. Iron deficiency alters the iFGF23-to-cFGF23 ratio. After initiation of iron treatment, cFGF23 strongly decreased. This case report illustrates the limitation of cFGF23 assays and urges clinicians to be aware that cFGF23 concentrations do not necessarily reflect iFGF23 concentrations and that alternative causes for its elevation should be considered (eg, iron deficiency). © 2023 The Authors. published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

References

Green D, Mohorianu I, Piec I, Turner J, Beadsmoore C, Toms A . MicroRNA expression in a phosphaturic mesenchymal tumour. Bone Rep. 2017; 7:63-69. PMC: 5596358. DOI: 10.1016/j.bonr.2017.09.001. View

Florenzano P, Cipriani C, Roszko K, Fukumoto S, Collins M, Minisola S . Approach to patients with hypophosphataemia. Lancet Diabetes Endocrinol. 2020; 8(2):163-174. DOI: 10.1016/S2213-8587(19)30426-7. View

Imel E, Peacock M, Gray A, Padgett L, Hui S, Econs M . Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011; 96(11):3541-9. PMC: 3205884. DOI: 10.1210/jc.2011-1239. View

Pal R, Agrawal K, Gupta S, Bhansali A, Behera A, Bhadada S . Worsening of unrecognized tumour-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone. Endokrynol Pol. 2019; 71(1):102-103. DOI: 10.5603/EP.a2019.0045. View

Heijboer A, Levitus M, Vervloet M, Lips P, Ter Wee P, Dijstelbloem H . Determination of fibroblast growth factor 23. Ann Clin Biochem. 2009; 46(Pt 4):338-40. DOI: 10.1258/acb.2009.009066. View

Imel E, Liu Z, McQueen A, Acton D, Acton A, Padgett L . Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone. 2016; 86:98-105. PMC: 4839198. DOI: 10.1016/j.bone.2016.03.005. View

Ratsma D, Zillikens M, van der Eerden B . Upstream Regulators of Fibroblast Growth Factor 23. Front Endocrinol (Lausanne). 2021; 12:588096. PMC: 7952762. DOI: 10.3389/fendo.2021.588096. View

van Vuren A, Gaillard C, Eisenga M, van Wijk R, van Beers E . The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research. Front Physiol. 2019; 10:304. PMC: 6443968. DOI: 10.3389/fphys.2019.00304. View

Wheeler J, Clinkenbeard E . Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. Curr Mol Biol Rep. 2019; 5(1):8-17. PMC: 6582956. DOI: 10.1007/s40610-019-0110-9. View

10.

Bosman A, Campos-Obando N, Medina-Gomez C, Voortman T, Uitterlinden A, Zillikens M . Serum Phosphate, BMI, and Body Composition of Middle-Aged and Older Adults: A Cross-Sectional Association Analysis and Bidirectional Mendelian Randomization Study. J Nutr. 2021; 152(1):276-285. PMC: 8754515. DOI: 10.1093/jn/nxab351. View

11.

Imel E, Econs M . Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012; 97(3):696-706. PMC: 3319220. DOI: 10.1210/jc.2011-1319. View

12.

David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V . Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2015; 89(1):135-46. PMC: 4854810. DOI: 10.1038/ki.2015.290. View

13.

Edmonston D, Wolf M . FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2019; 16(1):7-19. DOI: 10.1038/s41581-019-0189-5. View

14.

Chande S, Bergwitz C . Role of phosphate sensing in bone and mineral metabolism. Nat Rev Endocrinol. 2018; 14(11):637-655. PMC: 8607960. DOI: 10.1038/s41574-018-0076-3. View

15.

Hartley I, Gafni R, Roszko K, Brown S, de Castro L, Saikali A . Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia. J Bone Miner Res. 2022; 37(11):2174-2185. PMC: 9712269. DOI: 10.1002/jbmr.4702. View

16.

Bosman A, Palermo A, Vanderhulst J, de Beur S, Fukumoto S, Minisola S . Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases. Calcif Tissue Int. 2022; 111(4):367-379. PMC: 9474374. DOI: 10.1007/s00223-022-01005-8. View

17.

Bosman A, van den Beld A, Feelders R, Zillikens M . Cortisol and Phosphate Homeostasis: Cushing's Syndrome Is Associated With Reversible Hypophosphatemia. Front Endocrinol (Lausanne). 2021; 12:733793. PMC: 8515286. DOI: 10.3389/fendo.2021.733793. View

18.

Lewerin C, Ljunggren O, Nilsson-Ehle H, Karlsson M, Herlitz H, Lorentzon M . Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study. Bone. 2017; 98:1-8. DOI: 10.1016/j.bone.2017.02.005. View